GPR119 is expressed in insulin-producing beta cells where it modulates insulin release, thus making it a very attractive therapeutic target for metabolic disorders. GPR119 is activated by oleoylethanolamide (OEA) and by a novel selective small-molecule (PSN632408) which, when administered to high-fat-fed rats, suppresses food intake and reduces body weight gain. Another small molecule full-agonist (AR231453) enhances glucose-dependent insulin release, and improves oral glucose tolerance in wild-type mice, but not in GPR119 knock-out mice.
|Product Description||Human GPR119 Receptor-expressing GPCR (G protein-coupled receptor) division-arrested cells.|
|Product Type||EZCells™ DA|
|Receptor||Free Fatty Acid|
|Therapeutic Area||metabolic & gastrointestinal|
|Related Services||Membrane Preparation, GPCR Screening|
|Genbank Accession Number||NM_178471|
|References||Soga, T., Ohishi T. et al (2005) Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. BBRC: 326: 744-751.
Overton, H.A., Babbs, A.J. (2006) Deoprhanization of a G protein –coupled recepto
|Mycoplasma Status||Negative (MycoAlert Kit)|
|Growth media||Ham's F12, 10% FBS, 1% NEAA, 400 µg/mL G418|
|Storage and Packaging|
|Packaging||Cryopreserved irradiated cells, 6 million cells per vial|
|Storage Recommendation||liquid nitrogen|
|Quantity||6 million cells|
|Specification Sheet||Download PDF Document|